RxDoctor Payments Data

Charla Evans, DO

Family Medicine · Mobile, ALNPI 1770697500

Payments from drug & device makers

$6,198in general payments, 2019–2025

Across 440 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$991
  • Lilly USA, LLC$628
  • Pfizer$391
  • Amgen$309
  • Sanofi-aventis U.S. LLC$287
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,13099%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,198 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$61,019
Medicare patients
142
Services billed
3,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide331$346,871
MounjaroTirzepatide184$206,664
LinzessLinaclotide97$79,696
JardianceEmpagliflozin70$72,869
TrulicityDulaglutide67$66,392
GemtesaVibegron68$54,141
EliquisApixaban58$51,335
FarxigaDapagliflozin Propanediol49$48,634
Tresiba Flextouch U-100Insulin Degludec64$40,476
VascepaIcosapent Ethyl54$35,194
RybelsusSemaglutide25$34,806
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$34,598
MyrbetriqMirabegron49$32,289
Tresiba Flextouch U-200Insulin Degludec14$26,450
Repatha SureclickEvolocumab37$22,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,017$381,677356 claims
Lilly USA, LLCMounjaro, Trulicity$628$273,056251 claims
Boehringer IngelheimJardiance, Stiolto Respimat$170$86,14588 claims
AbbVieLinzess$991$79,69697 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$266$60,330101 claims
Sumitomo Pharma America, Inc.Gemtesa$227$54,14168 claims
PfizerEliquis$391$51,33558 claims
AstraZenecaFarxiga$230$48,63449 claims
Astellas Pharma US IncMyrbetriq$102$32,28949 claims
Johnson & JohnsonXarelto$45$16,80327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →